Trials / Completed
CompletedNCT02320032
An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia
A Phase 1, Randomized, Open-Label Study Evaluating the Pharmacokinetics of Various Dosing Regimens of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 140 (actual)
- Sponsor
- Alkermes, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of various doses and dosing intervals of aripiprazole lauroxil.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aripiprazole Lauroxil | Gluteal IM injection, given once every 4 to 8 weeks |
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2016-04-01
- Completion
- 2016-04-01
- First posted
- 2014-12-19
- Last updated
- 2018-08-29
Locations
16 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02320032. Inclusion in this directory is not an endorsement.